Clinical Trial Update: A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis [Phase 2]

View source ↗

Summary

KZR-616, an immunoproteasome inhibitor, was studied in a Phase 2 trial for active polymyositis and dermatomyositis by Kezar Life Sciences; the study is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Polymyositis

Drugs mentioned

• KZR-616 (KZR-616)

Snippet

Sponsor: Kezar Life Sciences, Inc. | Conditions: Polymyositis, Dermatomyositis | Phase 2 | Status: COMPLETED | Results posted: 2024-01-03